

Journal of Hepatology

E-submissions and author instructions:
<http://mc.manuscriptcentral.com/jhep>

Contents: Volume 50 · Issue 4 · April 2009

EASL News

- | | | |
|-----|---------------------------------|----------------------------------|
| 639 | To friends who have passed away | J.-M. Pawlotsky (France) |
| 640 | Professor Jean-Pierre Benhamou | D.C. Valla, D. Dhumeaux (France) |
| 642 | Andrés T. Blei, MD | V. Arroyo (Spain) |

Editorials

- | | | |
|-----|---|------------------------------|
| 644 | Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice | P. Lampertico (Italy) |
| 648 | Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future | C. Cammà, S. Petta (Italy) |
| 652 | Antiviral therapy in HCV-infected cirrhotics awaiting liver transplantation: A costly strategy for mixed virological results | B. Roche, D. Samuel (France) |
| 655 | Hepatocellular carcinoma in HIV-infected patients comes of age: The convergence of epidemiology and treatment effectiveness | M. Sulkowski (USA) |
| 659 | Modern diagnosis of hepatocellular carcinoma: Utilization of liver biopsy and genomic markers | J.A. Marrero (USA) |

Forum on Liver Transplantation

- | | | |
|-----|-------------------------------|---|
| 662 | Who should get a liver graft? | P.-A. Clavien (Switzerland) |
| 664 | Who should get a liver graft? | R.B. Freeman, N. Jamieson, D.E. Schaubel, R.J. Porte, F.G. Villamil (USA, UK, The Netherlands, Argentina) |

Original Articles

Viral Hepatitis

- | | | |
|-----|---|--|
| 674 | Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy | J.G.P. Reijnders, S.D. Pas, M. Schutten, R.A. de Man, H.L.A. Janssen (The Netherlands) |
| | <i>Human Study</i> | <i>See Editorial, pages 644–647</i> |
| 684 | Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients | N. Merchante, I. de los Santos-Gil, D. Merino, M. González-Serrano, J.A. Mira, J. Sanz-Sanz, E. Fernández-Fuertes, J. Ruiz-Morales, J. del Valle, J. Macías, A. Moro, J.A. Pineda (Spain) |
| | <i>Human Study</i> | <i>See Editorial, pages 648–651</i> |
| 693 | Acute infection with a single hepatitis C virus strain in dialysis patients: Analysis of adaptive immune response and viral variability | L. Weseslindtner, C. Neumann-Haefelin, S. Viazov, A. Haberstroh, J. Kletzmayer, J.H. Aberle, J. Timm, S.R. Ross, R. Klausner-Braun, T.F. Baumert, M. Roggendorf, R. Thimme, H. Holzmann (Austria, Germany, France) |
| | <i>Human Study</i> | |

- 705 Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection
Human Study
- K.-A. Kim, W. Lin, A.W. Tai, R.-X. Shao, E. Weinberg, C.B. De Sa Borges, A.K. Bhan, H. Zheng, Y. Kamegaya, R.T. Chung (USA, Republic of Korea)

- 712 Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients
Human Study *See Editorial, pages 648–651*
- C.-Y. Dai, J.-F. Huang, M.-Y. Hsieh, N.-J. Hou, Z.-Y. Lin, S.-C. Chen, M.-Y. Hsieh, L.-Y. Wang, W.-Y. Chang, W.-L. Chuang, M.-L. Yu (Taiwan)

Transplantation

- 719 Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study
Human Study *See Editorial, pages 652–654*
- J.A. Carrión, E. Martínez-Bauer, G. Crespo, S. Ramírez, S. Pérez-del-Pulgar, J.C. García-Valdecasas, M. Navasa, X. Forns (Spain)

Liver Failure, Growth and Cancer

- 729 Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels
Human Study
- T. Kumada, H. Toyoda, S. Kiriya, Y. Sone, M. Tanikawa, Y. Hisanaga, A. Kanamori, H. Atsumi, M. Takagi, S. Nakano, T. Arakawa, M. Fujimori (Japan)
- 736 Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study
Human Study *See Editorial, pages 655–658*
- D. Salmon-Ceron, E. Rosenthal, C. Lewden, V. Bouteloup, T. May, C. Burty, F. Bonnet, D. Costagliola, E. Jougl, C. Semaille, P. Morlat, P. Cacoub, G. Chêne, the ANRS EN19 Mortalité Study Group and Mortavic (France)
- 746 The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma
Human Study *See Editorial, pages 659–661*
- L. Di Tommaso, A. Destro, J.Y. Seok, E. Balladore, L. Terracciano, A. Sangiovanni, M. Iavarone, M. Colombo, J.J. Jang, E. Yu, S.Y. Jin, E. Morenghi, Y.N. Park, M. Roncalli (Italy, Republic of Korea, Switzerland)

Molecular and Cell Biology

- 755 Leukocyte transmigration in inflamed liver: A role for endothelial cell-selective adhesion molecule
A. Khandoga, S. Huettinger, A.G. Khandoga, H. Li, S. Butz, K.-W. Jauch, D. Vestweber, F. Krombach (Germany)
- 766 miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: An essential role for apoptosis
C.-J. Guo, Q. Pan, D.-G. Li, H. Sun, B.-W. Liu (China)
- 779 Generation of cytotoxicity against hepatitis delta virus genotypes and quasispecies by epitope modification
Y.-H. Huang, J.-C. Wu, W.-L. Peng, T.-I. Huo, H.-H. Shih, K.-H. Lan, C.-W. Su, S.-D. Lee (Taiwan)

Genetic and Metabolic Liver Disease

- 789 Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH
Human Study
- F. Caballero, A. Fernández, A.M. De Lacy, J.C. Fernández-Checa, J. Caballería, C. García-Ruiz (Spain, USA)
- 797 Influence of ethnicity on histological differences in non-alcoholic fatty liver disease
Human Study
- S.R. Mohanty, T.N. Troy, D. Huo, B.L. O'Brien, D.M. Jensen, J. Hart (USA)

Reviews

- 805 Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B
D.-S. Chen (Taiwan)

- 817 Clinical trial design and evidence-based outcomes in the study of liver diseases J.M. Croswell, B.S. Kramer (USA)

Letters to the Editor

- 827 Autoimmunity in primary biliary cirrhosis: An alternative view at initiation and function of anti-mitochondrial autoantibodies P.A. Berg (Germany)
- 828 What is the actual role of diagnosis and how to assess it? A. Colli, M. Fraquelli (Italy)
- 829 What is the actual role of diagnosis and how to assess it: Reply S.H. Mehta, B. Lau, N.H. Afdhal, D.L. Thomas (USA)

Case Report

- 831 Surgical management of portal hypertension in Felty's syndrome: A case report and literature review H. Stock, Z. Kadry, J.P. Smith (USA)

Journal Club

- 836 MELD–Na as a prognostic score for cirrhotic patients: Hyponatremia and ascites are back in the game D. Samuel (France)
- 838 Are pigs more human than mice? R. Oude Elferink, U. Beuers (The Netherlands)

Announcements

842

Registration of Clinical Trials

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004; 351:1250–1251 and *New Engl J Med* 2005; 352:2437–2438.

Cover Figure Clinical trial design and evidence-based outcomes in the study of liver diseases. The pyramid of evidence represents a general hierarchy of preferred clinical study designs. As one moves up the pyramid, the potential for bias is reduced (*see article by Croswell and Kramer on page 817*)

Available online at www.sciencedirect.com

 **ScienceDirect**
for online access via your library